受强制性开放获取政策约束的文章 - Gaurav Goyal了解详情
无法在其他位置公开访问的文章：2 篇
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease
L Chang, B Qiao, H Cai, H Lin, M Duan, J Li, D Zhou, G Goyal, C Sun, ...
Leukemia 37 (11), 2297-2300, 2023
强制性开放获取政策： 国家自然科学基金委员会
Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
D Yi, RS Go, GJ Ruan, NN Bennani, MV Shah, KL Rech, A Ravindran, ...
Blood 144, 3181, 2024
强制性开放获取政策： National Institute for Health Research, UK
可在其他位置公开访问的文章：35 篇
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
G Goyal, A Ravindran, JR Young, MV Shah, NN Bennani, MM Patnaik, ...
Haematologica 105 (2), 348, 2019
强制性开放获取政策： US National Institutes of Health
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
G Goyal, A Tazi, RS Go, KL Rech, JL Picarsic, R Vassallo, JR Young, ...
Blood, The Journal of the American Society of Hematology 139 (17), 2601-2621, 2022
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1
J Razanamahery, EL Diamond, F Cohen-Aubart, KH Plate, G Lourida, ...
Haematologica 105 (1), e5, 2020
强制性开放获取政策： US National Institutes of Health
Efficacy of BRAF‐Inhibitor Therapy in BRAFV600E‐Mutated Adult Langerhans Cell Histiocytosis
AZ Hazim, GJ Ruan, A Ravindran, JP Abeykoon, C Scheckel, R Vassallo, ...
The Oncologist 25 (12), 1001-1004, 2020
强制性开放获取政策： US National Institutes of Health
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis
G Goyal, JP Abeykoon, M Hu, JR Young, MV Shah, NN Bennani, TG Call, ...
American journal of hematology 96 (5), E146, 2021
强制性开放获取政策： US National Institutes of Health
Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset
G Goyal, AC Bartley, S Funni, J Inselman, ND Shah, AL Marshall, ...
Leukemia 32 (6), 1414-1420, 2018
强制性开放获取政策： US National Institutes of Health
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
G Goyal, SV Rajkumar, MQ Lacy, MA Gertz, FK Buadi, A Dispenzieri, ...
Leukemia 33 (5), 1273-1277, 2019
强制性开放获取政策： US National Institutes of Health
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
G Goyal, D Lau, AM Nagle, R Vassallo, KL Rech, JH Ryu, ...
Blood, The Journal of the American Society of Hematology 133 (14), 1607-1610, 2019
强制性开放获取政策： US National Institutes of Health
Nivolumab (N)‐AVD improves progression‐free survival compared to brentuximab vedotin (BV)‐AVD in advanced stage (AS) classic Hodgkin lymphoma (HL): results of SWOG S1826
AF Herrera, M LeBlanc, SM Castellino, H Li, SC Rutherford, AM Evens, ...
Hematological Oncology 41, 33-35, 2023
强制性开放获取政策： US National Institutes of Health
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
A Aaroe, R Kurzrock, G Goyal, AM Goodman, H Patel, G Ruan, G Ulaner, ...
Blood Advances 7 (15), 3984-3992, 2023
强制性开放获取政策： US National Institutes of Health
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
AA Acosta-Medina, PG Kemps, TCE Zondag, JP Abeykoon, J Forma-Borst, ...
Blood 142 (18), 1570-1575, 2023
强制性开放获取政策： US National Institutes of Health
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease
JP Abeykoon, TL Lasho, S Dasari, KL Rech, WK Ranatunga, MK Manske, ...
American journal of hematology 97 (3), 293-302, 2022
强制性开放获取政策： US National Institutes of Health
Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms
G Goyal, A Ravindran, Y Liu, R He, MV Shah, NN Bennani, MM Patnaik, ...
Haematologica 105 (2), e84, 2020
强制性开放获取政策： US National Institutes of Health
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
A Mahipal, SH Tella, A Kommalapati, G Goyal, H Soares, A Neuger, ...
Investigational new drugs 37, 473-481, 2019
强制性开放获取政策： US National Institutes of Health
Impact of the COVID-19 pandemic on treatment patterns for patients with metastatic solid cancer in the United States
RB Parikh, SU Takvorian, D Vader, E Paul Wileyto, AS Clark, DJ Lee, ...
JNCI: Journal of the National Cancer Institute 114 (4), 571-578, 2022
强制性开放获取政策： US National Institutes of Health
Long-term outcomes among adults with Langerhans cell histiocytosis
G Goyal, AA Acosta-Medina, JP Abeykoon, C Dai, A Ravindran, ...
Blood Advances 7 (21), 6568-6578, 2023
强制性开放获取政策： US National Institutes of Health
Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma
SH Desai, MA Spinner, K David, V Bachanova, G Goyal, B Kahl, K Dorritie, ...
American journal of hematology 98 (3), 464-471, 2023
强制性开放获取政策： US National Institutes of Health
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
S Zanwar, JP Abeykoon, S Dasari, A Ravindran, JR Young, ...
Blood cancer journal 12 (6), 97, 2022
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定